Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

2.

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaal3986. doi: 10.1126/scitranslmed.aal3986.

3.

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.

Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC.

Oncotarget. 2017 Jun 27;8(26):42343-42358. doi: 10.18632/oncotarget.16216.

4.

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.

Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP.

Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16.

5.

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.

Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC.

Mol Cancer Ther. 2016 May;15(5):783-93. doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29.

6.

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.

J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.

7.

Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes.

Rong JX, Klein JL, Qiu Y, Xie M, Johnson JH, Waters KM, Zhang V, Kashatus JA, Remlinger KS, Bing N, Crosby RM, Jackson TK, Witherspoon SM, Moore JT, Ryan TE, Neill SD, Strum JC.

PPAR Res. 2011;2011:179454. doi: 10.1155/2011/179454. Epub 2011 Oct 15.

8.

MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1.

Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, Waters KM.

Mol Endocrinol. 2009 Nov;23(11):1876-84. doi: 10.1210/me.2009-0117. Epub 2009 Oct 9.

9.

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F.

Diabetes. 2008 Feb;57(2):332-9. Epub 2007 Nov 16.

10.

Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.

Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, Okamoto Y, Mattie MD, Higashiyama H, Asano S, Strum JC, Ryan TE.

Diabetes. 2007 Jul;56(7):1751-60. Epub 2007 Apr 24.

11.

Rosiglitazone induces mitochondrial biogenesis in mouse brain.

Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A.

J Alzheimers Dis. 2007 Mar;11(1):45-51.

PMID:
17361034
12.

PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats.

Yang B, Lin P, Carrick KM, McNulty JA, Clifton LG, Winegar DA, Strum JC, Stimpson SA, Pahel GL.

Biochem Biophys Res Commun. 2005 Aug 19;334(1):176-82.

PMID:
15993383
13.

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.

Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, Winegar DA, Strum JC, Stimpson SA, Pahel GL.

BMC Pharmacol. 2004 Oct 18;4:23.

14.

GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.

Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK.

J Pharmacol Exp Ther. 2005 Feb;312(2):718-25. Epub 2004 Oct 8.

PMID:
15475592
15.

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.

Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI.

J Biol Chem. 2003 Mar 28;278(13):11303-11. Epub 2002 Dec 19.

16.

The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.

Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ.

J Biol Chem. 2003 Mar 28;278(13):11312-9. Epub 2002 Dec 19.

17.

Tissue expression profiling using real-time PCR.

Strum JC, Carrick KM, Stuart JS, Martensen SA.

Curr Protoc Pharmacol. 2002 Nov;Chapter 6:Unit 6.9. doi: 10.1002/0471141755.ph0609s18.

PMID:
22294081
18.

Recovery and expression of messenger RNA from postmortem human brain tissue.

Cummings TJ, Strum JC, Yoon LW, Szymanski MH, Hulette CM.

Mod Pathol. 2001 Nov;14(11):1157-61.

21.

Lipid second messengers. A role in cell growth regulation and cell cycle progression.

Strum JC, Ghosh S, Bell RM.

Adv Exp Med Biol. 1997;407:421-31. Review. No abstract available.

PMID:
9321986
22.

Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling.

Ghosh S, Strum JC, Bell RM.

FASEB J. 1997 Jan;11(1):45-50. Review.

PMID:
9034165
24.
25.

Identification of conditions that facilitate the expression of GST fusions as soluble, full-length proteins.

Ghosh S, Basu S, Strum JC, Basu S, Bell RM.

Anal Biochem. 1995 Mar 1;225(2):376-8. No abstract available. Erratum in: Anal Biochem 1995 Jul 20;229(1):151.

PMID:
7762811
26.

1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells.

Strum JC, Small GW, Pauig SB, Daniel LW.

J Biol Chem. 1994 Jun 3;269(22):15493-7.

27.

The cysteine-rich region of raf-1 kinase contains zinc, translocates to liposomes, and is adjacent to a segment that binds GTP-ras.

Ghosh S, Xie WQ, Quest AF, Mabrouk GM, Strum JC, Bell RM.

J Biol Chem. 1994 Apr 1;269(13):10000-7.

29.

Phospholipase D hydrolysis of choline phosphoglycerides is selective for the alkyl-linked subclass of Madin-Darby canine kidney cells.

Daniel LW, Huang C, Strum JC, Smitherman PK, Greene D, Wykle RL.

J Biol Chem. 1993 Oct 15;268(29):21519-26.

30.

Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride.

Strum JC, Nixon AB, Daniel LW, Wykle RL.

Biochim Biophys Acta. 1993 Jul 21;1169(1):25-9.

PMID:
8334146
32.

Lysophospholipase D.

Wykle RL, Strum JC.

Methods Enzymol. 1991;197:583-90. No abstract available.

PMID:
1646942

Supplemental Content

Loading ...
Support Center